General
Preferred name
CEFOPERAZONE
Synonyms
Medocef ()
Cefob ()
CEFOPERAZONE DIHYDRATE ()
cefoperazone ()
Cefobis ()
CEFOPERAZONE SODIUM ()
Cefoperazone (sodium salt) ()
Cefoperaone Sodium Salt ()
CP 52640-2 ()
Peracef ()
T-1551 ()
CP-52,640-2 ()
Cefoperazone (as sodium) ()
CP-526402 ()
Sodium cefoperazone ()
Cefobid ()
Cefoperazone sodium salt ()
NSC-758173 ()
CP-52640-2 ()
P&D ID
PD010964
CAS
62893-19-0
62893-20-3
Tags
covalent binder
natural product
drug
available
Approved by
FDA
First approval
1982
Drug Status
investigational
approved
withdrawn
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Indicated for the treatment of following infections caused by susceptible bacteria:[label]; ; 1) Respiratory tract infections caused by _S. pneumoniae_, _H. influenzae_, _S. aureus_ (penicillinase and non-penicillinase producing strains), _S. pyogenes_ (Group A beta-hemolytic streptococci), _P. aeruginosa_, _Klebsiella pneumoniae_, _E. coli_, _Proteus mirabilis_, and Enterobacter species.; ; 2) Peritonitis and other intra-abdominal infections caused by _E. coli_, _P. aeruginosa_, and anaerobic gram-negative bacilli (including _Bacteroides fragilis_).; ; 3) Bacterial septicemia caused by _S. pneumoniae_, _S. agalactiae_, _S. aureus_, _Pseudomonas aeruginosa_, _E. coli_, _Klebsiella_ spp., _Klebsiella pneumoniae_, Proteus species (indole-positive and indole-negative), _Clostridium_ spp. and anaerobic gram-positive cocci.; ; 4) Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa.; ; 5) Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci.; ; 6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa.; ; 7) Enterococcal Infections. Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, _in vitro_ susceptibility testing may not correlate directly with _in vivo_ results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.
DESCRIPTION Cefoperazone is a semisynthetic, third generation cephalosporin and belongs to the β-lactam class of antibacterial compounds . (GtoPdb)
Compound Sets
22
Axon Medchem Screening Library
3123
Cayman Chemical Bioactives
16113
ChEMBL Approved Drugs
CHEMBL507674
CHEMBL1200482
ChEMBL Drugs
CHEMBL507674
CHEMBL1200482
CovBinderInPDB
CBR005096
CBR005097
Drug Repurposing Hub
DrugBank
DB01329
DrugBank Approved Drugs
DB01329
DrugCentral
543
DrugCentral Approved Drugs
543
DrugMAP
DM53PV8
DrugMAP Approved Drugs
DM53PV8
Enamine BioReference Compounds
Guide to Pharmacology
12025
MedChem Express Bioactive Compound Library
HY-B0210
HY-B0210A
Natural product-based probes and drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
cefoperazone-cefobid
cefoperazone-sodium
TargetMol Bioactive Compound Library
T6437
Withdrawn 2.0
1027
External IDs
64
Properties
(calculated by RDKit )
Molecular Weight
645.14
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
5
Aromatic Ring Count
2
cLogP
-1.11
TPSA
220.26
Fraction CSP3
0.4
Chiral centers
3.0
Largest ring
6.0
QED
0.14
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
Antibacterial
antibiotic
Bacterial
Antibiotics,Bacterial
Indication
gram-negative bacterial infections
MOA
bacterial cell wall synthesis inhibitor
ATC
J01DD62
J01DD12
Biosynthetic Origin
Peptide (beta-Lactam)
Therapeutic Class
Antimicrobial
Antibiotics
Source data